Related Experiment Videos

[Efficiency and safety of carvedilol treatment in high risk hypertensive patients]

Xiu-li Zhao1, Dai-yi Hu,

  • 1Department of Cardiology, People's Hospital, Peking University, Beijing 100044, China.

Zhonghua Nei Ke Za Zhi
|April 21, 2006
PubMed

Insights

Carvedilol effectively treats high-risk hypertensive patients, showing similar safety and efficiency to primary hypertensive patients. This beta-blocker improves blood pressure and lipid profiles in those with cardiovascular risk factors.

Area of Science:

  • Cardiology
  • Pharmacology
  • Internal Medicine

Background:

  • Hypertension management requires careful consideration of patient risk factors.
  • High-risk hypertensive patients often have comorbidities like NIDDM, lipid disorders, or renal impairment.
  • Carvedilol is a beta-blocker with alpha-blocking activity, used for hypertension and heart failure.

Purpose of the Study:

  • To assess the efficacy and safety of carvedilol in high-risk hypertensive individuals.
  • To compare carvedilol's effectiveness in high-risk versus primary hypertensive patients.
  • To evaluate carvedilol's impact on metabolic parameters in high-risk populations.

Main Methods:

  • A comparative study involving 379 high-risk hypertensive patients and 364 primary hypertensive patients.
  • Carvedilol administration followed by monitoring of blood pressure, heart rate, serum glucose, lipid profile, and creatinine.
  • Statistical analysis to compare outcomes between the two groups.

Main Results:

  • Carvedilol significantly reduced blood pressure and heart rate in both high-risk and primary hypertensive groups.
  • High-risk patients showed significant reductions in serum glucose, total cholesterol (TC), triglycerides (TG), and LDL cholesterol.
  • Treatment efficiency rates were high and statistically similar between groups (97.75% vs. 98.32%).

Conclusions:

  • Carvedilol demonstrates comparable efficacy and safety in high-risk hypertensive patients as in primary hypertensive patients.
  • The drug is effective in improving cardiovascular and metabolic parameters in patients with hypertension and risk factors.
  • Carvedilol represents a safe and effective treatment option for a broad spectrum of hypertensive patients.
Abstract

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation, vasodilation, and...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...